Substitutional impact on biological activity of new water soluble Ni(II) complexes: Preparation, spectral characterization, X-ray crystallography, DNA/protein binding, antibacterial activity and in vitro cytotoxicity

A comprehensive review on anti-inflammatory, antibacterial, anticancer and antifungal properties of several bivalent transition metal complexes

Transition metal complexes have been recognized as possible therapeutic agents, attributed to their special biological actions, including anti-inflammatory, antibacterial, antifungal, and anticancer. The pharmacological perspective connected with Copper (Cu), Cobalt (Co), Nickel (Ni), Manganese (Mn), Palladium (Pd), Zinc (Zn), and Platinum (Pt) metal(II) complexes is comprehensively explored in-depth in this research. The complexes show unique coordination chemistry and modes of action that help interactions with biological targets, including DNA binding, enzyme inhibition, and the formation of reactive oxygen species. All the metal(II) complexes showed notable potential impact in their perspective activity. Conspicuously, Co(II) and Ni(II) complexes show better antibacterial and antifungal action, while Cu(II) and Zn(II) combinations show higher anti-inflammatory activity. While research is constantly investigating alternative metal-based anticancer drugs like Pd(II), which seem to have lowered side effects, Pt(II) complexes especially cisplatin continue to be the benchmark in cancer treatment. Although the possible pharmacological actions are motivating, problems with toxicity and biocompatibility still provide major difficulties, especially in relation to Cd(II) and Hg(II) complexes. Strategies like ligand modification, nanoparticle-based delivery, and prodrug methods are used to increase selectivity and reduce side effects related to metal complexes. This review compiles the most recent developments and continuous research, thereby shedding light on the potential revolutionary power of metal(II) complexes in medical therapy. Understanding their mechanisms and enhancing their safety profiles will help us open the path to creative ideas for addressing some of the most urgent medical issues of today.

Synthesis, DNA/BSA binding studies and in vitro biological assay of nickel(II) complexes incorporating tridentate aroylhydrazone and triphenylphosphine ligands

Two new nickel (II) triphenylphosphine complexes derived from tridentate aroylhydrazone ligands [H2L1 = 2-hydroxy-3-methoxybenzylidene)benzohydrazone and H2L2 = N'-(2-hydroxy-3-methoxybenzylidene)-2-hydroxybenzoylhydrazone] and triphenylphosphine were prepared and their molecular structures were determined by single crystal X-ray diffraction analysis. Both nickel(II) complexes showed slightly distorted square planar geometry with one tridentate aroylhydrazone ligand coordinated through ONO donor atoms and one triphenylphosphine ligand coordinated to the nickel center through the phosphorus atom. DNA interaction studies indicated that both complexes possessed higher affinity to herring sperm DNA (HS-DNA) than the corresponding free aroylhydrazone ligand. Molecular docking investigations showed that both complexes could bind to DNA through intercalation of the phenyl rings between adjacent base pairs in the double helix. Meanwhile, bovine serum albumin (BSA) binding studies revealed the complexes could effectively interact with BSA and change the secondary structure of BSA. Further pharmacological evaluations of the synthesized complexes by in vitro antioxidant assays demonstrated high antioxidant activity against NO· and O2˙- radicals. The anticancer activity of each complex was assessed through in vitro cytotoxicity assays (CCK-8 kit) toward A549 and MCF-7 cancer cell and normal L-02 cell lines. Significantly, the Ni(II) complex derived from H2L1 ligand was found to be more effective cytotoxic toward MCF-7cancerous cell with the IC50 value equaled 9.7 μM, which showed potent cytotoxic activity over standard drug cisplatin.

Novel half-sandwich iridium(iii) imino-pyridyl complexes showing remarkable in vitro anticancer activity

Seven novel half-sandwich Ir^III cyclopentadienyl complexes, [(η⁵-Cp^x)Ir(N^N)Cl]PF₆, have been prepared and characterized, where Cp^x is Cp* or the biphenyl derivative Cp^xbiph (C₅Me₄C₆H₄C₆H₅), and the N^N-chelating ligands are imino-pyridyl Schiff-bases. The X-ray crystal structures of complexes 2A, 2B, and 3A have been determined. Excitingly, most of the complexes show potent antiproliferative activity towards A549 and HeLa cancer cells, except for Cp* complex 1A towards HeLa cells. Cp^xbiph complex 2B displayed the highest potency, about 19 and 6 times more active than the clinically used drug cisplatin toward A549 and HeLa cells, respectively. These complexes undergo hydrolysis, and the kinetics data have been calculated. DNA binding has been studied by interaction with nucleobases 9-ethylguanine and 9-methyladenine, cleavage of plasmid DNA, and interaction with ctDNA. Interaction with DNA does not appear to be the major mechanism of action. Protein binding (bovine serum albumin, BSA) has been established by UV-Vis, fluorescence and synchronous spectroscopic studies. The stability of complex 2B in the presence of GSH was evaluated. The complexes catalytically convert coenzyme NADH to NAD⁺via hydride transfer. Cp^xbiph complexes 2B and 4B induce cell apoptosis and arrest cell cycles at the S and G₂/M phases towards A549 cancer cells and increase the reactive oxygen species dramatically, which appear to contribute to the remarkable anticancer activity.

3-Acetyl-8-methoxy-2[H]-chromen-2-one derived Schiff bases as potent antiproliferative agents: Insight into the influence of 4(N)-substituents on the in vitro biological activity

A series of 3-acetyl-8-methoxycoumarin appended thiosemicarbazones (1-4) was prepared from the reaction of 3-acetyl-8-methoxycoumarin with 4(N)-substituted thiosemicarbazides in a view of ascertaining their biological properties with the change of N-terminal substitution in the thiosemicarbazide moiety. Comprehensive characterization was brought about by various spectral and analytical methods. The molecular structures of all the compounds were determined by single crystal X-ray diffraction analysis. Binding studies with Calf thymus DNA (CT-DNA) and proteins such as Bovine Serum Albumin (BSA) and Human Serum Albumin (HSA) indicated an intercalative mode of binding with DNA and static quenching mechanism with proteins. The compounds cleaved plasmid DNA (pBR322) and acted well as free radical scavengers. A good spectrum of antimicrobial activity was observed against four bacterial and five fungal pathogens. The compounds exhibited profound antiproliferative activity on MCF-7 (human breast cancer) and A549 (human lung carcinoma) cell lines. Assay on human normal keratinocyte cell line HaCaT showed that the compounds were non-toxic to normal cells.

Lysosome targeted drugs: rhodamine B modified N^N-chelating ligands for half-sandwich iridium(iii) anticancer complexes

We designed and synthesized four rhodamine-modified half-sandwich iridium complexes ([(η⁵-Cp^x)Ir(N^N)Cl]PF₆).